L&H files for Chapter 11 bankruptcy

Article

Faced with plummeting revenue, mounting shareholder lawsuits, and investigations by the U.S. Securities and Exchange Commission (SCAN, 10/11/00) and the Nasdaq stock exchange, Belgian voice recognition technology provider Lernout & Hauspie has filed for

Faced with plummeting revenue, mounting shareholder lawsuits, and investigations by the U.S. Securities and Exchange Commission (SCAN, 10/11/00) and the Nasdaq stock exchange, Belgian voice recognition technology provider Lernout & Hauspie has filed for Chapter 11 bankruptcy protection.

L&H has partnerships and strategic alliances with most PACS and RIS vendors. The firm says it will continue operating as it seeks to reorganize its debt.

The SEC and Nasdaq began investigating L&H earlier this year in relation to questionable accounting practices. The SEC is focusing on L&H's business dealings in Korea and Singapore. Revenue in those areas appeared to be strong last quarter but could turn out to be part of a complicated bundle of investments connected to the FLV Fund, a Belgian venture capital company linked to L&H founders Jo Lernout and Pol Hauspie. n

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.